+129.1%
ASML vs GSK
+31.2%
+97.9%
-22.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.2% | -1.9% | +6.1% | +4.4% |
| 7D | +1.1% | -1.8% | +2.9% | +1.3% |
| 30D | +2.2% | -2.2% | +4.4% | +2.4% |
| 3M | -2.3% | -1.8% | -0.5% | -2.5% |
| 6M | +23.0% | -10.6% | +33.6% | +25.4% |
| YTD | +61.1% | +4.4% | +56.6% | +62.6% |
| 1Y | +129.1% | +30.4% | +98.7% | +127.3% |
| All | +129.1% | +31.2% | +97.9% | +127.3% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling